Peapod Lane Capital LLC Decreases Holdings in Kyverna Therapeutics, Inc. $KYTX

Key Points

• Peapod Lane Capital cut its stake in Kyverna Therapeutics by 42.3% in Q4, selling 134,940 shares and ending the period with 183,820 shares worth about $1.73 million (roughly 0.42% of the company and 1.5% of the fund's portfolio).
• Kyverna shares were down 12.5%, trading around $8.95 with a market cap of $541.7M, a negative P/E (-2.45), and reported quarterly EPS of ($0.80) while analysts project about -3.18 EPS for the year.
• Analyst sentiment is mixed but tilted positive: four Buys and one Sell give an average rating of "Moderate Buy" and a consensus price target of $28.67, amid recent divergent notes from Weiss Ratings (Sell) and HC Wainwright (Buy, $20 target).

Peapod Lane Capital LLC decreased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 42.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 183,820 shares of the company's stock after selling 134,940 shares during the period. Kyverna Therapeutics comprises approximately 1.5% of Peapod Lane Capital LLC's portfolio, making the stock its 29th biggest holding. Peapod Lane Capital LLC owned about 0.42% of Kyverna Therapeutics worth $1,728,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in KYTX. Public Employees Retirement System of Ohio bought a new position in shares of Kyverna Therapeutics in the third quarter worth approximately $28,000. Qube Research & Technologies Ltd bought a new position in shares of Kyverna Therapeutics in the second quarter worth approximately $43,000. Capital Advisors Inc. OK bought a new position in shares of Kyverna Therapeutics in the third quarter worth approximately $60,000. Rhumbline Advisers grew its holdings in shares of Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock worth $61,000 after purchasing an additional 5,694 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of Kyverna Therapeutics in the third quarter worth approximately $77,000. Institutional investors own 18.08% of the company's stock.

Kyverna Therapeutics Stock Down 12.5%

Shares of Kyverna Therapeutics stock opened at $8.95 on Friday. The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.11. Kyverna Therapeutics, Inc. has a 12-month low of $1.92 and a 12-month high of $13.67. The company has a market cap of $541.74 million, a P/E ratio of -2.45 and a beta of 2.62. The company's fifty day simple moving average is $8.61 and its two-hundred day simple moving average is $8.11.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). Research analysts anticipate that Kyverna Therapeutics, Inc. will post -3.18 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on KYTX shares. Weiss Ratings restated a "sell (d-)" rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Kyverna Therapeutics in a report on Thursday. Finally, Wall Street Zen cut shares of Kyverna Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Kyverna Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $28.67.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.